Please login to the form below
BCMA
This page shows the latest BCMA news and features for those working in and with pharma, biotech and healthcare.
bluebird bio to separate oncology and rare diseases units
Oncology Newco will assume responsibility for a number of bluebird bio’s current oncology assets, including its investigational BCMA-targeting CAR T therapy idecabtagene vicleucel (ide-cel), which is currently being ... In addition, Oncology Newco will
Latest news
-
GSK’s anti-BCMA drug leads crowded CHMP recommendations
BCMA protein is expressed at varying levels in myeloma patients and BCMA membrane expression is universally detected in myeloma cell lines. ... The positive recommendation from the CHMP means that GSK’s Blenrep will be the first anti-BCMA treatment
-
GSK pays $50m upfront to tap Immatics’ cell therapy platform
Barron has said Zejula is one of three that he expects to drive the regrowth of GSK as an oncology player, along with recently-filed BCMA antibody-drug conjugate belantamab mafodotin
-
Bluebird bio leans on pipeline and Zynteglo launch as revenues fall
Bluebird is in partnership with BMS for a BCMA-targeting cell therapy – bb2121 or ide-cel – which recently demonstrated positive top-line results in multiple myeloma.
-
FDA begins speedy review of BMS’ CAR-T liso-cel
In addition to liso-cel, BMS has another CAR-T therapy in the pipeline – its bluebird bio-partnered BCMA-targeting therapy bb2121 for multiple myeloma. ... However, on that front there are a number of rivals already developing anti-BCMA therapeutics,
-
FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma
If approved will become first BCMA targeting drug for myeloma. GlaxoSmithKline looks set to win the race to bring a BCMA-targeting drug to market for multiple myeloma, after gaining a ... This includes belantamab mafodotin, which is a particularly
More from news
Approximately 6 fully matching, plus 47 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... BCMA to which Celgene already has access.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Highlights in haematologic malignancy from ASH 2018
Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Account Director
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- Nucleus Global announces a trio of promotions
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Pfizer introduces new logo in a ‘shift from commerce to science’
- PHE study finds people who have had COVID-19 can still transmit the virus
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- New study identifies drugs that are safe to use in COVID-19 treatment
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Pegasus
Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
